The OSIC Data Repository was instrumental to Coreline Soft’s development of an estimated FVC (eFVC) metric that can be calculated from chest HRCT scans.
During our 2025 Annual Member Meeting, Dr. Ryoungwoo Jang (장령우 박사), clinical research lead for Coreline Soft, discussed how eFVC shows promise as a tool for monitoring disease status, predicting progression, and assessing response to pharmaceutical treatments.
How can we improve patient care with AI-imaging biomarkers?
During our 2025 Annual Member Meeting, Dr. George Harston, chief medical and innovation officer at Brainomix, spoke about how OSIC has catalyzed Brainomix’s work in ILD and pulmonary fibrosis – both in clinical care and clinical trials.
How can AI-based quantification of airway wall thickening, airway dilation, and mucus impaction provide meaningful patient phenotypes?
During our 2025 Annual Member Meeting, Thironas’s Chief Innovation Officer Dr. Jean–Paul Charbonnier shared the results of several years of dedicated work to move airway analysis beyond single CT metrics toward comprehensive, quantitative characterization of airway conditions.
OSIC member GMV is using our data repository in its work with SEPI-IA, a publicly funded Spanish research and innovation initiative aimed at developing AI tools for medical imaging of rare respiratory diseases.
Carlos Illana Alejandro, GMV’s head of advanced health products, discussed the initiative’s objectives and work to date during our 2025 Annual Member Meeting, and explained how collaborating with OSIC is helping fuel GMV’s research.
The OSIC Data Repository is the world’s largest and most diverse ILD database. Our partner for this platform, Sandra Stapleton and her team at VIDA, are constantly working to improve its features and make its plethora of powerful data even more accessible to users.
Sandra explored the repository’s latest enhancements during our 2025 Annual Member Meeting and demonstrated how these features streamline data access and accelerate research workflows.
“Early detection and intervention are the keys to impacting outcomes in pulmonary fibrosis, COPD, and other lung diseases,” said Dr. Lida Hariri, associate professor of pathology at Harvard Medical School and Massachusetts General Hospital, during our 2025 Annual Member Meeting.
Dr. Hariri discussed her work with optical coherence tomography and the different ways she’s been using this minimally invasive technology to help support early diagnosis and monitoring in ILDs.
Could interpretable survival models predict disease progression and patient outcomes better than traditional methods?
David Barber, a professor at University College London and OSIC’s computational science lead, spoke to this question during our 2025 Annual Member Meeting and discussed how his CenTime model can help drive more accurate predictions.
How do we tackle the complex data that comes from sarcoidosis – a rare, inflammatory disease characterized by granulomas that form in one or more organs – and create something we can work from to help find a cure?
The Foundation for Sarcoidosis Research (FSR) presented this challenge during our 2025 Annual Member Meeting. Elise Hoover, FSR’s vice president of research, discussed how FSR is helping combat sarcoidosis from all perspectives through its diverse research initiatives, Clinical Data Registry, and global collaborations.
Can AI help detect clinical deterioration in bronchiectasis sooner? Can advances in phenotyping and endotyping enable precision medicine approaches? How can we extend our current knowledge of this disease out into the world?
Dr. Kevin Brown (National Jewish Health), Dr. Helmut Prosch (Medical University of Vienna and president of the European Society of Thoracic Imaging), and Prof. Luca Richeldi (Fondazione Policlinico Universitario A. Gemelli IRCCS) examined the evolving landscape of bronchiectasis research, clinical care, and quantitative imaging during a panel discussion at our 2025 Annual Member Meeting. They provided an integrated view of the disease, from clinical presentation and epidemiology to imaging interpretation and emerging AI-enabled approaches.
In the second episode of The Lung Lab, Dr. Lisa Lancaster – director of the Interstitial Lung Disease (ILD) program at Vanderbilt University and chief medical officer at Endeavor Biometrics – discusses the long and winding road many lung disease patients often face on their way to diagnosis.
A pulmonologist with over 25 years of experience and 85 clinical trials behind her, Dr. Lancaster is one of the most respected voices in the ILD space. She shares her perspective on the emotional challenges of delivering life-changing news, the promise of emerging therapies, and the future of ILD treatment she hopes to see.
